<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Vaccine strategies of SARS-CoV and MERS-CoV.</p>
 </caption>
 <alt-text id="alttext0045">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="2">Vaccine strategy</th>
    <th rowspan="2">Process of production</th>
    <th colspan="2">Result and reference
     <hr/>
    </th>
   </tr>
   <tr>
    <th>SARS-CoV</th>
    <th>MERS-CoV</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Inactivated virus vaccines</td>
    <td>Virus particles are inactivated by physical or chemical methods</td>
    <td>1. Induces S-specific antibody responses and neutralizing antibodies in mice (1:7393) and rabbit (1:2060), neutralizes pseudotyped SARS-CoV
     <xref rid="bib47" ref-type="bibr">
      <sup>47</sup>
     </xref>.
     <break/>2. Induces neutralizing antibodies in mice in ferret (1: 128-256), neutralizes SARS-CoV; reduces the virus titer in the respiratory tract, and provides protective immunity
     <xref rid="bib48" ref-type="bibr">
      <sup>48</sup>
     </xref>.
    </td>
    <td>Induces S-specific antibody responses and neutralizing antibodies in mice (&gt;1:10
     <sup>3</sup>); neutralizes pseudotyped MERS-CoV
     <xref rid="bib49" ref-type="bibr">
      <sup>49</sup>
     </xref>.
    </td>
   </tr>
   <tr>
    <td>Live-attenuated virus vaccines</td>
    <td>Genomes are mutated by mutagenesis or targeted deletions</td>
    <td>1. Induces SARS-CoV-specific antibody responses and neutralizing antibodies in 6-week-old mice (1:10
     <sup>2</sup>‒10
     <sup>3</sup>) and 12-month-old mice (1:10
     <sup>2</sup>‒10
     <sup>3</sup>), neutralizes SARS-CoV Urbani strain; elicts T-cell responses and protectes all mice (6-week-old/12-month-old) against challenge with virulent virus
     <xref rid="bib55" ref-type="bibr">
      <sup>55</sup>
     </xref>.
     <break/>2. Induces SARS-CoV-specific antibody responses and T cell responses in BALB/c and hACE2 Tg mice; protectes 60%‒70% of mice against challenge with virulent virus
     <xref rid="bib56" ref-type="bibr">
      <sup>56</sup>
     </xref>.
     <break/>3. The TRN-rewired SARS-CoV is attenuated and protect against lethal SARS-CoV challenge
     <xref rid="bib57" ref-type="bibr">
      <sup>57</sup>
     </xref>.
    </td>
    <td>rMERS-CoV-E generated by reverse genetics system is a replication-competent, propagation-defective virus
     <xref rid="bib58" ref-type="bibr">
      <sup>58</sup>
     </xref>.
    </td>
   </tr>
   <tr>
    <td>Nucleic acid-based vaccines</td>
    <td>Genetically engineered DNA/mRNA encode antigenic compounds</td>
    <td>Induces S-specific antibody responses and neutralizing antibodies in 80% subjects, neutralizes pseudotyped SARS-CoV; elicts T-cell responses in all subjects
     <xref rid="bib60" ref-type="bibr">
      <sup>60</sup>
     </xref>.
    </td>
    <td>1. Induces S-specific antibody responses and neutralizing antibodies in mice (&gt;1:10
     <sup>2</sup>), camels (1:600‒700) and rhesus macaques (&gt;1:10
     <sup>2</sup>), neutralizes MERS-CoV strain (EMC/2012); elicts T-cell responses in rhesus macaques and protects 100% of rhesus macaques from viral challenge
     <xref rid="bib61" ref-type="bibr">
      <sup>61</sup>
     </xref>.
     <break/>2. Induces S1-specific antibody responses and neutralizing antibodies in 77% subjects, neutralizes MERS-CoV strain (EMC/2012); elicts T-cell responses in 64% subjects
     <xref rid="bib63" ref-type="bibr">
      <sup>63</sup>
     </xref>.
    </td>
   </tr>
   <tr>
    <td>Viral-vector vaccines</td>
    <td>Inserting foreign gene units into the viral genome by homologous recombination</td>
    <td>1. Induces neutralizing antibodies in African green monkeys (≈1:16) immunized with BHPIV3-SARS-S vector vaccine, neutralizes SARS-CoV; protectes all african green monkeys against challenge with virulent virus
     <xref rid="bib69" ref-type="bibr">
      <sup>69</sup>
     </xref>.
     <break/>2. Induces neutralizing antibodies in mice (1:160) immunized with RV-SARS-S vector vaccine; neutralizes SARS-CoV
     <xref rid="bib70" ref-type="bibr">
      <sup>70</sup>
     </xref>.
    </td>
    <td>1. Induces neutralizing antibodies in mice (1: 64‒128) immunized with MVA-MERS-S vector vaccine, neutralizes MERS-CoV; elict T-cell responses and reduces virus titers in the lung
     <xref rid="bib71" ref-type="bibr">
      <sup>71</sup>
     </xref>.
     <break/>2. Induces S-specific antibody responses and neutralizing antibodies in mice (&gt;1:10
     <sup>3</sup>) immunized with Ad5/Ad41-MERS-S vector vaccine, neutralizes pseudotyped MERS-CoV; elicts T-cell responses
     <xref rid="bib72" ref-type="bibr">
      <sup>72</sup>
     </xref>.
     <break/>3. Induces S-specific IgG subtype antibody (IgG1 and IgG2a) and neutralizing antibodies in mice (&gt;1:10
     <sup>3</sup>) immunized with Ad5-MERS-S1 vector vaccine, neutralizes MERS-CoV strain (EMC/2012)
     <xref rid="bib73" ref-type="bibr">
      <sup>73</sup>
     </xref>.
     <break/>4. Induces S1-specific IgG subtype antibody (IgG1 and IgG2a) and neutralizing antibodies in mice (1:10
     <sup>2</sup>‒10
     <sup>3</sup>/1:10
     <sup>3</sup>‒10
     <sup>4</sup>) immunized with rAd5-S1/F/CD40 vaccine, neutralizes pseudotyped and live MERS-CoV
     <xref rid="bib74" ref-type="bibr">
      <sup>74</sup>
     </xref>.
    </td>
   </tr>
   <tr>
    <td>Virus-like particle (VLPs) vaccines</td>
    <td>Genes clone viral structural proteins into expression system</td>
    <td>1. Induce neutralizing antibodies in mice (1: 200± 97.7), neutralizes SARS-CoV; reduces virus titers in the lung
     <xref rid="bib78" ref-type="bibr">
      <sup>78</sup>
     </xref>.
     <break/>2. Induce neutralizing antibodies in mice (1:875‒1525), neutralizes SARS-CoV Urbani strain; reduces virus titers in the lung and protects all mice against challenge with virulent virus
     <xref rid="bib79" ref-type="bibr">
      <sup>79</sup>
     </xref>.
    </td>
    <td>Induced RBD-specific antibody responses and neutralizing antibodies in mice (1: 320), neutralizes pseudotyped MERS-CoV; elict T-cell responses
     <xref rid="bib80" ref-type="bibr">
      <sup>80</sup>
     </xref>.
    </td>
   </tr>
   <tr>
    <td>Subunit vaccines</td>
    <td>Antigenic components including immunogenic pathogen fragment without nucleic acid</td>
    <td>1. Induce S-specific antibody responses and neutralizing antibodies in mice (1:4.0×10
     <sup>3</sup>±3.5×10
     <sup>2</sup>), neutralizes SARS-CoV BJ01 strain; protects 80% of the mice from the virus challenge
     <xref rid="bib81" ref-type="bibr">
      <sup>81</sup>
     </xref>.
     <break/>2. Induces RBD-specific antibody responses and neutralizing antibodies in mouse (1:5.8×10
     <sup>4</sup>±4.9×10
     <sup>3</sup>/1:1.0×10
     <sup>3</sup>±2.4×10
     <sup>2</sup>), neutralizes pseudotyped and live SARS-CoV; elict T-cell responses and protects all mice against challenge with virulent virus
     <xref rid="bib82" ref-type="bibr">
      <sup>82</sup>
     </xref>.
    </td>
    <td>Induced RBD-specific antibody responses and neutralizing antibodies in in rhesus monkey (1:1600), neutralizes pseudotyped MERS-CoV; elicts T-cell responses and reduces virus titers
     <xref rid="bib85" ref-type="bibr">
      <sup>85</sup>
     </xref>.
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
